• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

间质肿瘤浸润淋巴细胞(sTILs)与印尼三阴性乳腺癌的更高分级和更低分期相关。

Stromal Tumor Infiltrating Lymphocytes (sTILs) Were Associated with a Higher Grade and a Lower Stage of Indonesian Triple Negative Breast Cancers.

机构信息

Department of Anatomic Pathology, Faculty of Medicine, Public Health and Nursing Universitas Gadjah Mada, Indonesia.

Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing Universitas Gadjah Mada, Indonesia.

出版信息

Asian Pac J Cancer Prev. 2022 Aug 1;23(8):2749-2754. doi: 10.31557/APJCP.2022.23.8.2749.

DOI:10.31557/APJCP.2022.23.8.2749
PMID:36037130
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9741910/
Abstract

OBJECTIVE

This study aimed to investigate the association of sTILs with clinicopathological parameters and overall survival (OS) in patients with triple negative breast cancer (TNBC).

METHODS

One hundred and twenty-five paraffin embedded tissue of patients with TNBC, collected from Dr. Sardjito General Hospital Yogyakarta, Indonesia, between 2008-2017, were used in this study. Stromal TILs were examined from hematoxylin and eosin (H&E)-stained samples, and classified as either low or high score using 20% cut-off. Analysis of the association of sTILs with clinicopathological parameters, relative risk (RR) and OS used 95% confidence interval (CI) with significance set as p<0.05.

RESULTS

The higher proportion of TNBC patients in this study were ≥40 years old (83.3%), high tumor grade (68%), tumor stage >IIIa (56%), alive (50.4%), and with low sTILs (54.4%). The results showed significant association between sTILs and a higher grade or a lower stage of tumor (B = 0.259, 95%CI = 0.090-0.468, p = 0.004 and B = -0.255, 95%CI = -0.433 - -0.080, p = 0.005, respectively ). Meanwhile sTILs were not associated with age at diagnosis (B = 0.027, 95%CI = -0.193 - 0.264  p = 0.758 nor 3-year OS of patients (HR = 0.342, 95%CI = 0.41 - 1.43  p = 0.402).

CONCLUSION

The results indicate that sTILs may serve as an additional pathological parameter for TNBC.

摘要

目的

本研究旨在探讨间质肿瘤浸润淋巴细胞(sTILs)与三阴性乳腺癌(TNBC)患者临床病理参数和总生存期(OS)的关系。

方法

本研究使用了 2008 年至 2017 年间从印度尼西亚日惹萨迪吉托综合医院收集的 125 例 TNBC 患者的石蜡包埋组织。使用苏木精和伊红(H&E)染色样本检测基质 TILs,并使用 20%的截断值将其分为低或高评分。使用 95%置信区间(CI)分析 sTILs 与临床病理参数、相对风险(RR)和 OS 的关系,显著性设置为 p<0.05。

结果

本研究中,TNBC 患者≥40 岁的比例较高(83.3%),高肿瘤分级(68%)、肿瘤分期>IIIa(56%)、存活(50.4%)和低 sTILs(54.4%)的比例较高。结果表明,sTILs 与肿瘤分级较高或分期较低之间存在显著相关性(B = 0.259,95%CI = 0.090-0.468,p = 0.004 和 B = -0.255,95%CI = -0.433 - -0.080,p = 0.005)。同时,sTILs 与诊断时的年龄(B = 0.027,95%CI = -0.193 - 0.264,p = 0.758)或患者 3 年 OS 均无相关性(HR = 0.342,95%CI = 0.41-1.43,p = 0.402)。

结论

结果表明,sTILs 可能成为 TNBC 的另一个病理参数。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f558/9741910/019e227ab3e9/APJCP-23-2749-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f558/9741910/61af508c403d/APJCP-23-2749-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f558/9741910/00e41670c042/APJCP-23-2749-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f558/9741910/019e227ab3e9/APJCP-23-2749-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f558/9741910/61af508c403d/APJCP-23-2749-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f558/9741910/00e41670c042/APJCP-23-2749-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f558/9741910/019e227ab3e9/APJCP-23-2749-g003.jpg

相似文献

1
Stromal Tumor Infiltrating Lymphocytes (sTILs) Were Associated with a Higher Grade and a Lower Stage of Indonesian Triple Negative Breast Cancers.间质肿瘤浸润淋巴细胞(sTILs)与印尼三阴性乳腺癌的更高分级和更低分期相关。
Asian Pac J Cancer Prev. 2022 Aug 1;23(8):2749-2754. doi: 10.31557/APJCP.2022.23.8.2749.
2
Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy.早期三阴性乳腺癌(TNBC)患者未接受辅助化疗时肿瘤浸润淋巴细胞的预后价值。
Ann Oncol. 2019 Dec 1;30(12):1941-1949. doi: 10.1093/annonc/mdz395.
3
Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer.CD4和CD8阳性T细胞浸润增加表明三阴性乳腺癌的一个亚组预后良好。
Breast Cancer Res Treat. 2016 Apr;156(2):237-47. doi: 10.1007/s10549-016-3743-x. Epub 2016 Mar 9.
4
Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers.肿瘤浸润淋巴细胞与预后:早期三阴性乳腺癌患者的汇总分析。
J Clin Oncol. 2019 Mar 1;37(7):559-569. doi: 10.1200/JCO.18.01010. Epub 2019 Jan 16.
5
Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.来自两项III期随机辅助乳腺癌试验(ECOG 2197和ECOG 1199)的三阴性乳腺癌中肿瘤浸润淋巴细胞的预后价值
J Clin Oncol. 2014 Sep 20;32(27):2959-66. doi: 10.1200/JCO.2013.55.0491.
6
Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy.肿瘤浸润淋巴细胞改善了三阴性乳腺癌患者接受无蒽环类药物新辅助化疗的结局。
Clin Cancer Res. 2024 May 15;30(10):2160-2169. doi: 10.1158/1078-0432.CCR-24-0106.
7
Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial.SWOG9313c 试验中三阴性乳腺癌患者 DNA 损伤免疫反应特征的验证。
J Clin Oncol. 2019 Dec 20;37(36):3484-3492. doi: 10.1200/JCO.19.00693. Epub 2019 Oct 28.
8
Reproducibility and predictive value of scoring stromal tumour infiltrating lymphocytes in triple-negative breast cancer: a multi-institutional study.三阴性乳腺癌中肿瘤间质浸润淋巴细胞评分的可重复性和预测价值:一项多机构研究。
Breast Cancer Res Treat. 2018 Aug;171(1):1-9. doi: 10.1007/s10549-018-4825-8. Epub 2018 May 17.
9
BI-RADS Ultrasound Lexicon Descriptors and Stromal Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.BI-RADS 超声词汇描述符与三阴性乳腺癌间质肿瘤浸润淋巴细胞。
Acad Radiol. 2022 Jan;29 Suppl 1(Suppl 1):S35-S41. doi: 10.1016/j.acra.2021.06.007. Epub 2021 Jul 14.
10
Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers.肿瘤浸润淋巴细胞对新辅助治疗的三阴性乳腺癌病理完全缓解的预测价值。
Diagn Pathol. 2018 Aug 31;13(1):66. doi: 10.1186/s13000-018-0743-7.

本文引用的文献

1
A comparison between young and old patients with triple-negative breast cancer: biology, survival and metastatic patterns.年轻和老年三阴性乳腺癌患者的比较:生物学、生存和转移模式。
Breast Cancer Res Treat. 2020 Aug;182(3):643-654. doi: 10.1007/s10549-020-05727-x. Epub 2020 Jun 10.
2
Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis.三阴性乳腺癌患者肿瘤浸润淋巴细胞的预后价值:系统评价和荟萃分析。
BMC Cancer. 2020 Mar 4;20(1):179. doi: 10.1186/s12885-020-6668-z.
3
Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy.
早期三阴性乳腺癌(TNBC)患者未接受辅助化疗时肿瘤浸润淋巴细胞的预后价值。
Ann Oncol. 2019 Dec 1;30(12):1941-1949. doi: 10.1093/annonc/mdz395.
4
Associations in tumor infiltrating lymphocytes between clinicopathological factors and clinical outcomes in estrogen receptor-positive/human epidermal growth factor receptor type 2 negative breast cancer.雌激素受体阳性/人表皮生长因子受体2阴性乳腺癌中肿瘤浸润淋巴细胞的临床病理因素与临床结局之间的关联。
Oncol Lett. 2019 Feb;17(2):2177-2186. doi: 10.3892/ol.2018.9853. Epub 2018 Dec 19.
5
The clinical promise of immunotherapy in triple-negative breast cancer.免疫疗法在三阴性乳腺癌中的临床前景。
Cancer Manag Res. 2018 Dec 10;10:6823-6833. doi: 10.2147/CMAR.S185176. eCollection 2018.
6
Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers.肿瘤浸润淋巴细胞对新辅助治疗的三阴性乳腺癌病理完全缓解的预测价值。
Diagn Pathol. 2018 Aug 31;13(1):66. doi: 10.1186/s13000-018-0743-7.
7
Comparison of tumor-infiltrating lymphocytes of breast cancer in core needle biopsies and resected specimens: a retrospective analysis.核心针活检与切除标本中乳腺癌浸润淋巴细胞的比较:一项回顾性分析。
Breast Cancer Res Treat. 2018 Sep;171(2):295-302. doi: 10.1007/s10549-018-4842-7. Epub 2018 Jun 5.
8
Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer.抑制肿瘤:免疫检查点阻断治疗癌症的临床反应和耐药机制综述。
J Mol Biol. 2018 Jul 6;430(14):2014-2029. doi: 10.1016/j.jmb.2018.05.030. Epub 2018 May 22.
9
The presence of PD-1 positive tumor infiltrating lymphocytes in triple negative breast cancers is associated with a favorable outcome of disease.三阴性乳腺癌中程序性死亡受体1(PD-1)阳性肿瘤浸润淋巴细胞的存在与疾病的良好预后相关。
Oncotarget. 2017 Dec 27;9(5):6201-6212. doi: 10.18632/oncotarget.23717. eCollection 2018 Jan 19.
10
Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients.影响三阴性乳腺癌患者生存的临床和病理因素的大样本研究。
BMC Cancer. 2018 Jan 8;18(1):56. doi: 10.1186/s12885-017-3969-y.